S
Shasha Meng
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 5
Citations - 757
Shasha Meng is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Carcinogenesis & Ubiquitin ligase. The author has an hindex of 4, co-authored 4 publications receiving 686 citations.
Papers
More filters
Journal ArticleDOI
Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies
Selvaraju Veeriah,Barry S. Taylor,Shasha Meng,Fang Fang,Emrullah Yilmaz,Igor Vivanco,Manickam Janakiraman,Nikolaus Schultz,Aphrothiti J. Hanrahan,William Pao,Marc Ladanyi,Chris Sander,Adriana Heguy,Eric C. Holland,Philip B. Paty,Paul S. Mischel,Linda M. Liau,Timothy F. Cloughesy,Ingo K. Mellinghoff,Ingo K. Mellinghoff,David B. Solit,Timothy A. Chan +21 more
TL;DR: Inactivating somatic mutations and frequent intragenic deletions of PARK2 in human malignancies are described and strongly point to PARK2 as a tumor suppressor on 6q25.2–q27 in cancer.
Journal ArticleDOI
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Selvaraju Veeriah,Cameron Brennan,Shasha Meng,Bhuvanesh Singh,James A. Fagin,David B. Solit,Philip B. Paty,Dan Rohle,Igor Vivanco,Juliann Chmielecki,William Pao,Marc Ladanyi,William L. Gerald,Linda M. Liau,Timothy C. Cloughesy,Paul S. Mischel,Chris Sander,Barry S. Taylor,Nikolaus Schultz,John E. Major,Adriana Heguy,Fang Fang,Ingo K. Mellinghoff,Timothy A. Chan +23 more
TL;DR: PTPRD is shown to be a tumor suppressor on chromosome 9p that is involved in the development of GBMs and multiple human cancers and was found to dephosphorylate the oncoprotein STAT3.
Journal ArticleDOI
Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins
Yongxing Gong,Travis I. Zack,Luc G. T. Morris,Kan Lin,Ellen Hukkelhoven,Radhika Raheja,I-Li Tan,Sevin Turcan,Selvaraju Veeriah,Shasha Meng,Agnes Viale,Steven E. Schumacher,Perry Palmedo,Rameen Beroukhim,Timothy A. Chan +14 more
TL;DR: Parks2 regulates cyclin-CDK complexes, as does the CDK inhibitor p16, but acts as a master regulator of the stability of G1/S cyclins, a new class of cullin-RING–containing ubiquitin ligases targeting both cyclin D and cyclin E for degradation.
Journal ArticleDOI
14-3-3σ and p21 synergize to determine DNA damage response following Chk2 inhibition
Shasha Meng,Tali Arbit,Selvaraju Veeriah,Ingo K. Mellinghoff,Fang Fang,Igor Vivanco,Dan Rohle,Timothy A. Chan +7 more
TL;DR: It is shown that Chk2 depletion causes markedly increased sensitivity to DNA damage in p21-/-, 14-3-3σ-/- cells but not in cells lacking only one or none of these genes, and chk2 modulates the biological rheostat that determines whether a cancer cell undergoes arrest versus death after treatment with a chemotherapeutic agent.